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in tbe In Vivo Migl'1ltion of Neutropbils in Experimental
Escherichia coli Pyelonepbritis in Rats
Pascal R. Meylan and Michel P. Glauser From the Division des Maladies Infectieuses of the
Departement de Medecine Interne, Centre Hospita/ier
Universitaire Vaudois, Lausanne, Switzerland
In experimentalEscherichia colipyelonephritis,the bacterial multiplication in the kidney
parenchyma triggers a burst of neutrophil extravascular migration, as measured by the
myeloperoxidase (MPO) activity in the kidney, a marker for tissueneutrophil infiltration.
To test the mechanisms of in vivoneutrophil migration, pyelonephritiswas surgicallyin-
duced in rats that werethen either complement-depletedwith cobra venom factor (CYF),
resulting in a profound hypocomplementemia for 72 h after inoculation, or treated with
phenylbutazone (PB), a competitiveantagonist of bacterial chemotactic formylpeptides.
Compared to controls, CYF-and PB-treated animals killed when the neutrophil infiltra-
tion started (32h) had a significantly reduced neutrophil infiltration, as measured by kid-
neyMPO activity.This effect disappeared in animals killed 72 h after surgery, when neu-
trophil infiltration peaked. These data suggest that redundant chemotactic mechanisms
triggered neutrophilmigration. Inhibitingone of thesemechanisms only transiently delayed
neutrophil migration but did not affect the peak infiltration.
Recent experiments using a rat model of ascending
obstructive Escherichia coli pyelonephritis have
delineated the course of neutrophil polymorpho-
nuclear leukocyte infiltration in response to the mul-
tiplication of bacteria in the kidney parenchyma [1].
This model therefore offers the opportunity for
studying in vivo the mechanisms of neutrophil migra-
tion. In vitro experiments using the filter assay or
the "under-agarose migration assay" have demon-
strated that gradients of various chemoattractants
trigger chemotaxis, a directional migration of neu-
trophils [2]. The best known chemoattractants are
the complement-derived C5a and C5a-des-arg pep-
tides [3-5], the bacterial formylpeptides [6, 7], and
oxidized derivatives of arachidonic acid generated
through the lipooxygenase pathway, mainly leu-
kotriene B4 [8]. In vivo, the injection of these sub-
stances promotes the extravascular migration of neu-
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trophils [9]. During acute E. coli pyelonephritis,
bacteria multiplying within the kidney parenchyma
may produce chemotactic formylpeptides [7] and ac-
tivate the complement cascade by its alternate path-
way [10].
We used two approaches to assess the respective
role of these chemotactic substances in triggering the
migration of neutrophils into the kidney interstitial
space. First, cobra venom factor (CVF) was used to
deplete circulating complement in rats. Hypocom-
plementemia was checked by measuring levels of to-
tal serum hemolytic complement (CHso) and im-
munoreactive C3 and the capacity of the serum to
generate in vitro neutrophil migration upon zymo-
san activation. Second, rats were treated with phenyl-
butazone (PB), a competitive inhibitor of chemotac-
tic formylpeptides for neutrophil receptors [11-13],
in doses that prevented formylpeptide-induced neu-
tropenia in rabbits [12]. Some of the animals were
killed during the acute phase of pyelonephritis, and
the neutrophil infiltration of their kidney paren-
chyma was determined by measuring the my-
eloperoxidase (MPO) activity, an enzymatic marker
for neutrophil infiltration [1]. Another group of
animals was killed during the chronic phase of pye-
lonephritis, with the aim of correlating the effect of
any diminished neutrophil migration during the
acute phase with the development of pyelonephritic
scarring.
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Materials and Methods
In vitro experiments. (l) Complementlevelde-
terminations. The CHso wasmeasured according to
established procedures [14]. Immunoreactive C3levels
weredetermined by rocket immunoelectrophoresis
as described by Laurell (15) using a goat antiserum
to rat C3c (Nordic Immuno, Tilburg, Netherlands).
The serumchemotacticactivityupon zymosanac-
tivation wasdetermined in an under-agarosemigra-
tion assay. Pooled normal rat serum and test sera
were activated as follows. Quantities (5 mg each) of
washed zymosan (Sigma Chemical, S1. Louis) were
added to I-mL aliquots of serum, which were vor-
texedand incubated 60min at 37°C. After centrifu-
gation at 1000 g for 15 min, the supernatant washar-
vested and stored at - 70°C until tested. Agarose
plates (0.75070) were prepared by heating 0.3 g of
agarose(Seakem LE; FMC, Rockland,Me)in 32mL
of distilled water to 100°C. After cooling to 50°C,
4 mL of warm Medium 199 (concentration lOx)
containing Earle's salts (GIBCO Laboratories, Pais-
ley, UK), 4 mL of 7.5070 bovine serum albumin,
and 665 J.1L of7.5% NaHC03 wasadded. Aliquots
(2 mL each) were poured into 35 x lO-mm Petri
dishes(Falcon,Oxnard, Calif) and allowedto solid-
ify. Four pairs of 2A-mm-diameter wells were
punched out 4.6mm apart in eachdish and the plugs
gently removed by suctioning with a Pasteur pipette
[16]. The attractant well was loaded with 5 J.1L of
zymosan-activated serum and left to prediffuse for
2 h at 37°C in a humidified incubator with 7% CO2,
Neutrophils were then loaded (5 J.1L containing 2 x
105 cells) into the opposite well and left to migrate
for 2 h at 37°C with7% CO2• Migrationwasstopped
by cooling at 4°C until the cellswere counted. Cells
migratingout of the well were counted usinga Nikon
invertedmicroscopewith an ocular grid (LeitzPeri-
plan, Wetzlar, GDR) as described [16]. Each experi-
ment was done five times. The number of neutro-
phils migrating out of the wells wasproportional to
the reciprocal dilution of the pooled normal rat se-
rum. This relationship was used to determine the
titers of serum chemotactic activity of test sera. All
complement levels in test serawere expressed as per-
cent of the level in pooled normal rat serum.
(2) Serum bactericidal activity against E. coli.
The bactericidal effect of rat serum against E. coli
06:K5:Hl used for inducing pyelonephritis was
tested as suggestedbyTaylor[17]. The bacteria were
grownto midexponential phase (about 107 cfu/mL}
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in Tryptone soy broth (GIBCO), harvested by cen-
trifugation, and resuspended in gelatin-veronal-
calcium-magnesium buffer (Bio-Merieux, Lyon,
France) containing various concentrations of fresh
or heated (56°C, 1 h) pooled normal rat serum to
a finalvolume of 1mL. Thetesttubeswere incubated
in a rotatingwaterbath at 37°C.Aliquots were pipet-
ted out after 0, 1, 2, 3, and 6 h of incubation and
plated onto Columbia agar (GIBCO) with an auto-
matic device(Spiral SystemDS; IG, Zurich). Colo-
nies were counted after 24 h of incubation at 37°C
and viable counts were expressed as 10glO cfu/mL.
In vivo experiments. (1) Experimental design.
Ascending pyelonephritis was surgically induced
in rats as previously described [18, 19]. After re-
covering from anesthesia, the rats were randomly
assigned to one of three treatment groups. A first
group received two iv injectionsof 100units of CVF
(Lot S4131, Cordis Laboratories,Miami) 1and 32 h
after surgery. A control group received an identical
schedule of iv saline. A third group received im
phenylbutazone, 50 mg/kg per day for 3 d in two
divided doses, the first dose being administered on
the morning before surgery and the last dose at 72
h after surgery. One-third of the animals in each
treatment group were killed 32 h after surgery (the
time when neutrophil migration started), 72 h after
surgery(the time of peak neutrophil infiltration), or
2 mo after surgery (when chronickidneyscarringwas
fully established) [18]. Rats were killed as described
[1].
In each experiment, parameters were evaluatedas
follows. The incidence of gross, macroscopic pye-
lonephritis wasexpressed as the number of rats with
macroscopiclesionsof the left kidneyoverthe total
number of rats. Kidneys that do not display pye-
lonephritic lesionsharbor verylowbacterial counts
for a few days after inoculation and indicate a fail-
ure to inducepyelonephritis [19, 20]. Bacterial counts
in the kidney parenchyma were expressed as 10glO
cfu/g kidney tissue. In addition, the severityof the
inflammatory changes was assessed by measuring
the kidneyweight,whichprovidesa quantitative in-
dex of the severityof pyelonephritis. It increases in
proportion to suppuration during acutepyelonephri-
tis, whereas it decreases in proportion to the destruc-
tion of kidney tissue during chronic pyelonephritis
[1, 18, 19]. Tominimizethe effects of kidney weight
variation among animals, the ratio of the weightof
the left to the weightof the right kidney (L/R kid-
neyweightratio) wasused. This ratio also expresses
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the compensatory hypertrophy of the right kidney
that takes place during chronic pyelonephritis in
proportion to the extent of left kidney parenchyma
destruction [18]. This has been confirmed by func-
tional radioisotopic studies [1].
The kidney MPO activity in the kidney homoge-
nates, which has been shown to be a specific and sen-
sitive marker for kidney neutrophil infiltration, was
also measured [I]. This activity was expressed as
MPO activity units per kidney, taking into account
both the kidney weight and the dilution due to
homogenization. Blood samples from CVF-treated
and control rats killed during the acute phase were
left to clot for I h at room temperature. The serum
was harvested and stored at -70°C before comple-
ment level determinations.
(2) Preparation oj isolated neutrophils. Iso-
lated neutrophils for in vitro testing were obtained
in rats by ip injection of 5 mL of 30 mg/mL
Thioglycollate broth (Difco Laboratories, Detroit)
containing 2 IU/mL of heparin (Heparin Kabi; Kabi
AB, Stockholm). The peritoneal cavity was opened
aseptically 4 h later and washed with IOmL of ice-
cold Earle's balanced salt solution containing 7.5
mg/mL of bovine serum albumin (GIBCO) and
2 IU/mL of heparin. The washing fluid was har-
vested and the peritoneal cells were centrifuged at
100g, for 10 min. Hypotonic lysis of the red cells was
performed in distilled water (30 sec). Isotonicity was
restored by concentrated Earle's. The cells were
washed again by centrifugation, resuspended in
Earle's, and counted in a hemocytometer. Each rat
yielded rv2 x 107 cells. Trypan blue exclusion indi-
cated more than 95070 viability. Differential counts
on Wright's stained smears indicated that more than
98% of the cells were polymorphonuclear leukocytes.
(3) Statisticalanalysis. In vivo experiments were
performed twice and, because they gave reproduc-
ible results, the data were pooled for statistical anal-
ysis. Linear correlations were computed by the least-
squares method. Comparisons between groups were
done by the two-tailed Wilcoxon rank sum test. To
take into account the fact that three groups were
compared, the Bonferroni adjustment was used [21]
and the level of significance set at P = .025.
Results
In vitro experiments. The under-agarose migra-
tion assay was used as a functional assay for serum
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factors able to produce chemotactic substances upon
zymosan activation, especially serum C5 [3, 5]. In-
deed, the number of cells migrating toward the at-
tracting well was proportional to the concentration
of zymosan-activated pooled normal rat serum (fig-
ure I), suggesting that cell migration is an indicator
of the chemotactic substances in activated serum.
Figure 2 demonstrates the effect of CVF treatment
in rats with pyelonephritis on the CHso, immunoreac-
tive C3, and functional C5 levels. In rats killed 32
h after surgery, the CHso, C3, and functional C5 lev-
els were profoundly depressed in CVF-treated rats
compared with those in controls. In the group of rats
killed 72 h after surgery, CHso levels in CVF-treated
rats increased slightly but remained profoundly
depressed while C3 and functional C5 levels were
even lower than those in animals killed 32 h after
surgery. Preliminary experiments (data not shown)
have demonstrated that similar doses of CVF pro-
foundly depressed the complement levels within a
few hours after the injection. Thus, CVF-treated rats
had very low complement levels from the time of sur-
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Figure 1. Effect of zymosan activatedserum (ZAS)on
neutrophil migration in the agaroseassay, as measuredby
the number of neutrophils migrating toward the attract-
ingwell. Eachpoint represents the meanand standarddevi-
ation of five assays.
962 Meylan and Glauser
Figure 2. Complement levels in animals with pyelo-
nephritis killed 32and 72h after the inoculation. CHso:
totalserum hemolytic complement; C3: immunoreactive
C3; Chemotaxis: serum chemotactic activity uponzymo-
sanactivation, i.e., functional assay forserum C5. Sal =
saline-treated (controls); CVF = CVF-treated animals.
Results areexpressed aspercent ofthelevel found inpooled
normal ratserum. Columns represent means, andbars in-
dicate standard deviations of each group.
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gery until 72 h afterwards, and perhaps for a longer
time. In contrast, saline-treated animals with pye-
lonephritishad highercomplementlevels than those
found in pooled normal rat serum, probably result-
ing from the acute inflammatory reaction.
In vivoexperiments. Overall, 176 rats had sur-
gery to produce pyelonephritis. Fourteen of them
died soon after surgery, because of the anesthesia
or E. colisepticemia secondaryto severe pyelonephri-
tisas suggested bypost-mortemexamination and cul-
tures. As shownin table 1,theseearlydeathsoccurred
mainly among the CVF-treated animals and to a
lesserdegreeamong PB-treated animals killed 72 h
or 2 mo after surgery. Therefore, in these treatment
groups, the disappearanceof those animals with the
most severe pyelonephritisbefore the planned time
of sacrificemight haveintroduced a bias towardun-
derestimating the severityof pyelonephritis. In ad-
dition, neither CVF nor PB treatment significantly
influenced the incidenceof pyelonephritis(table 1).
In animals killed 32 h after surgery, both CVF-
and PB-treatment significantlyreducedMPO activ-
ity in their left kidneyscompared to that in controls
(figure 3).The medianMPO activitywasrespectively
19.6 activity units per kidney (CVF) and 13.1 activ-
ity units per kidney (PB) compared to 53.1 activity
units per kidney in controls (P < .01 for both com-
parisons). Thus, both treatments significantly re-
duced the early neutrophil migration into the kid-
Table 1. Effect of cobravenom factor (CVF) and phenylbutazone (PB) treatment on pyelonephritis.
Severity of pyelonephritis
No. of animals
Surviving With pyelo-
Overall inflammatory
response'[ Bacterial countsl
Time of until nephritis at
sacrifice"; treatment Operated sacrifice sacrifice (070) median (range) P median (range) P
32 h
Saline 20 20 16 (80) 1.39 (1.21-1.54) 8.36 (7.81-9.09)
CVF 19 19 15 (79) 1.36 (1.l1-1.57) .79 8.18 (7.39-9.06) .15
PB 20 20 16 (80) 1.24 (1.l3-1.48) <.01 7.92 (6.41-8.45) <.01
72h
Saline 18 17 11 (65) 1.76 (1.09-2.41) 8.84 (6.50-10.17)
CVF 20 20 18 (90) 2.00 (1.42-2.55) .15 9.43 (8.79-10.24) .035
PB 20 17 15 (83) 1.52 (0.92-1.77) .04 8.67 (7.76-9.74) .31
2 mo
Saline 20 20 18 (90) 0.65 (0.10-0.88) 4.93 (1.81-8.08)
CVF 20 13 13 (100) 0.64 (0.22-0.97) .94 5.10 (1.75-7.05) .61
PB 19 16 14 (88) 0.47 (0.17-0.98) .52 4.50 (1.73-6.78) .59
NOTE. P values refer to statistical comparisons (Wilcoxon) of each treatment group with controls.
* After surgery.
t Ratio of the weight of the left to the weight of the right kidney from animals with pyelonephritis.
t Log., cfu/g kidney tissue of animals with pyelonephritis.
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Figure 3. Left kidney myeloperoxidase (MPO)activity
of animals sacrificed 32 or 72 h after inoculation. Sal:
saline-treated (controls); CVF: cobravenom factor-treated;
PB: phenylbutazone-treated. Closedcircles represent the
kidney MPO activityof animalswith macroscopic signs
of pyelonephritis andhighbacterial counts, while opencir-
des are from animalswithout macroscopic pyelonephri-
tis and withvery lowbacterialcounts «102 cfu/g of kid-
neytissue), Bars represent medians, P values (two-tailed
Wilcoxon) are indicated beneath the columns.
ney parenchyma. However, despite continued CVF
or PB therapy until 72 h after inoculation, there was
no longer any significant reduction in the left kid-
ney MPO activity in CVF- or PB-treated animals
(P = .37 and .31, respectively). These findings show
that the initially reduced neutrophil infiltration was
transient, probably related to a delayed migration
induced by each treatment.
PB diminished the acute inflammatory swelling
of kidneys, as measured by the L/R kidney weight
32 72
Hours after bladder inoculation
The present experiments demonstrated that both
CVF and PB treatments were able to transiently re-
duce the in vivo neutrophil migration early during
pyelonephritis, an effect that was no longer appar-
ent at the time of peak kidney neutrophil infiltra-
tion [1]. It is possible that this transient effect of both
treatments on neutrophil migration might have been
a result of the CVF or PB treatment becoming in-
effective beyond 32 h after surgery.
With regard to CVF treatment, this was probably
not the case, because the CVF produced a prolonged
hypocomplementemia that lasted throughout the
treatment period. Particularly, the ability of serum
to produce chemotactic factors upon zymosan acti-
vation was strikingly depressed in CVF-treated rats
as demonstrated using the under-agarose migration
assay. In addition, in studies using animals used in
the present experiments and fluorescent antibodies
to rat C3, no CVF-treated animal shed demonstra-
ble C3-coated E. coli in the urine during acute pye-
lonephritis, in contrast to brisk fluorescent bacilli ob-
served in the urine of a majority of control animals.
In vitro experiments using fresh pooled normal rat
serum to coat E. coli in urine demonstrated that
fluorescence was observed with serum dilutions as
high as 1:200 [22].These observations suggest, there-
fore, that complement levels within the kidney tis-
sue werealso effectivelydepressed by CVF treatment.
PB treatment was administered in the present
study at doses that others have shown to completely
prevent the neutropenia induced in rabbits by iv in-
jection of the formylpeptide formyl-methionyl-
leucyl-phenylalanine [12]. Although a different ef-
ficacy of this drug in the rat can not be excluded,
ratio (table 1). This antiinflammatory effect of PB
was accompanied by a transient reduction of the bac-
terial counts in the pyelonephritic kidneys early af-
ter the production of pyelonephritis (32 h). In con-
trast, CVF treatment not only did not prevent the
inflammatory swelling, but also enhanced bacterial
multiplication to a near significant degree in the kid-
ney of animals killed 72 h after surgery, a fact prob-
ably related to the serum susceptibility of the E. coli
study strain (data not shown). When the rats were
killed 2 mo after surgery, the L/R kidney weight ra-
tio was similar in CVF-, PB-, and saline-treated
animals, reflecting a degree of pyelonephritic scar-
ring of similar severity.
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its effect on early neutrophil migration suggests that
the present doses wereeffective. Wehypothesize that
PB inhibited early neutrophil infiltration by inter-
fering with bacterial formylpeptide-mediated chemo-
taxis. However, it is possible that PB acted by another
mechanism involving inhibition of prostaglandin
synthesis.
In various experimental models of E. coli pye-
lonephritis, conflicting results have been reported
with respect to the effect of decomplementation on
neutrophil infiltration and inflammatory damage.
Sullivan et al. [23], using a rat model of hematoge-
nous pyelonephritis, as well as Roberts et al. [24],
using a model of ascending pyelonephritis in rhesus
monkeys, demonstrated a reduced neutrophilic in-
filtration in CVF-treated animals early after infec-
tion, but observations over periods longer than 48
h werenot performed. In contrast, Wilson et al. [25],
using a rat model of pyelonephritis induced by di-
rect intrarenal inoculation, did not observe a reduced
neutrophil infiltration in CVF-treated animals fol-
lowed for 4 d. Thus, these contradictory results might
reflect the fact that the short-term studies detected
transient reduction of neutrophil infiltration that was
not shown by studies with longer periods of obser-
vation.
In experimental models of bacterial diseases other
than pyelonephritis, similar findings of delayed neu-
trophil exudation have been observed. For instance,
Tuomanen et al. [26], using rabbits with experimen-
tal Streptococcus pneumoniae meningitis treated
with CVF, observed a delayed rise in cerebrospinal
fluid leukocyte counts. Toews et al. [27,28] observed
in experimental pneumococcal and Hemophilus in-
fluenzae pneumonia a significant neutrophil recruit-
ment into the lung of congenitally C5-deficient mice.
They concluded that chemotactic factors other than
C5a were produced in the alveoli, demonstrating the
redundancy of the chemotactic mechanisms after
pulmonary challenge with S. pneumoniae or H. in-
fluenzae. Similar conclusions might be drawn from
the results of the present experiments. Indeed, the
lack of a sustained efficacy of both CVF and PB
treatment at reducing the peak neutrophil infiltra-
tion observed here suggests that several independent
chemotactic mechanisms operated during acute pye-
lonephritis. We postulate that complement-derived
as well as bacterial formylpeptide chemotactic fac-
tors played an important role in triggering the neu-
trophil migration during the early inflammatory
response in vivo. Later on, other concurrent chemo-
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tactic mechanisms became powerful enough to in-
duce a neutrophil migration despite continued com-
plement depletion or inhibition of formylpeptide
receptors.
Recent evidence suggests that endothelial recog-
nition determinants for neutrophil adherence mole-
cules may playa role in regulating the extravascular
migration of inflammatory cells into inflamed tis-
sue [29]. These determinants are upregulated by li-
popolysaccharide and other inflammatory media-
tors and can facilitate the attachment of neutrophils
to the endothelium even in the absence of chemotac-
tic factors. They can also act with chemotactic fac-
tors to enhance transendothelial migration. There-
fore, in addition to chemotactic factors acting on
inflammatory cells, neutrophil infiltration might be
partially regulated by inflammatory substances act-
ing on endothelial cells. These observations might
thus be a concurrent explanation for neutrophil in-
filtration apparently independent of chemotactic
factors.
In the rat model of ascending pyelonephritis,
chronic renal scarring follows the irreversible tissue
damage that results from acute inflammatory
processes (1, 18, 19]. In the present experiments, nei-
ther CVF nor PB treatment resulted in any signifi-
cant protection against permanent kidney damage.
This observation is not invalidated by the early
deaths of CVF-treated animals to be killed at 72 h
and 2 mo after surgery. Indeed, the disappearance of
those rats with the most severepyelonephritis might
only lead to an underestimation of the median sever-
ity of pyelonephritis.This supports the interpretation
that pyelonephritis was at least as severe in CVF-
treated animals as in controls at these later times of
sacrifice. The fact that higher bacterial counts were
observed during acute pyelonephritis in CVF-treated
animals supports our previous findings (1, 19, 30]
that excessiveinfiltration and activation of neutro-
phils during the acute phase of pyelonephritis, not
bacterial virulence factors, is the major culprit
responsible for the tissue damage that leads to pye-
lonephritic scarring.
In conclusion, both CVF and PB treatments re-
duced early neutrophil infiltration during acute pye-
lonephritis. However, this reduction was only tran-
sient; peak neutrophil infiltration was not reduced.
This suggests that complement-derived as well as
bacterial formylpeptide chemotactic factors played
an important role in triggering neutrophil migration
during the early inflammatory response. Later on,
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other concurrent chemotactic mechanisms became
powerful enough to induce a neutrophil migration
despite continued complement depletion or inhibi-
tion of formylpeptide receptors. The similar peak
neutrophil infiltration resulted in chronic kidney
scarring of similar severity among the various treat-
ment groups, supporting the hypothesis that neutro-
phils, rather than bacterial virulence factors, play the
major role in the pathogenesis of pyelonephritic
scarring.
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